SG11201803794YA - Method for preventing or treating nosocomial pneumonia - Google Patents

Method for preventing or treating nosocomial pneumonia

Info

Publication number
SG11201803794YA
SG11201803794YA SG11201803794YA SG11201803794YA SG11201803794YA SG 11201803794Y A SG11201803794Y A SG 11201803794YA SG 11201803794Y A SG11201803794Y A SG 11201803794YA SG 11201803794Y A SG11201803794Y A SG 11201803794YA SG 11201803794Y A SG11201803794Y A SG 11201803794YA
Authority
SG
Singapore
Prior art keywords
gaithersburg
llc
way
medlmmune
medimmune
Prior art date
Application number
SG11201803794YA
Inventor
Hasan Jafri
Antonio Digiandomenico
Michael Mccarthy
Xiang-Qing Yu
Charles Stover
Brian Bishop
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG11201803794YA publication Critical patent/SG11201803794YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ires.. 00) (43) International Publication Date ..... ..sr ,„,„. 8 June 2017 (08.06.2017) W I P0 1 PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 2017/095744 Publication Al Number (51) International Patent Classification: (74) Agents: MARTIN, Cynthia, Lan et al.; Medlmmune, CO7H 21/04 (2006.01) A61K 39/104 (2006.01) LLC, One MedImmune Way, Gaithersburg, MD 20878 C12P 21/08 (2006.01) C07K 16/00 (2006.01) (US). A61K 39/00 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2016/063865 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 28 November 2016 (28.11.2016) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 62/260,935 30 November 2015 (30.11.2015) US TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: MEDIMMUNE, LLC [US/US]; One Medlm- mune Way, Gaithersburg, MD 20878 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: JAFRI, Hasan; MedImmune, LLC, One GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Medlmmune Way, Gaithersburg, MD 20878 (US). DIGI- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, ANDOMENICO, Anthony; Medlmmune, LLC, One TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Medlmmune Way, Gaithersburg, MD 20878 (US). MC- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, CARTHY, Michael; MedImmune, LLC, One MedImmune LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, MD 20878 YU, Xiang-Qing; Way, Gaithersburg, (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Medlmmune, LLC, One Medlmmune Way, Gaithersburg, GW, KM, ML, MR, NE, SN, TD, TG). MD 20878 (US). STOVER, Charles, K.; MedImmune, Declarations under Rule 4.17: LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). BISHOP, Brian; MedImmune, LLC, One Medlm- — as to applicant's entitlement to apply for and be a granted mune Way, Gaithersburg, MD 20878 (US). patent (Rule 4.170) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) [Continued on next page] Title: METHOD FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA (54) FIG.1 Study Day 12 4 8 15 22 29 50 4 )9 )9 )9 4^ - 19 Predose N -= 143 Day -7 to Day -1 Da 1 Treatment Arm 2: single IV dose of 1500 mg or 3000 mg MEIN3902 H Z LEI (/) Z Z 0 9-) N = 286 D ----49 LEP 0 0 (.t co ,.l LE_ 7 1 2 4 8 15 22 29 50 1\" i 1 1\" 1 N = 143 .4t — — * Treatment Arm single IV dose of placebo ll• Legend ll• ], It\"-- MED13902/piacebo administration in ii 01 Post-dose follow-up C:: , IN Il (57) : A method for preventing or treating nosocomial diseases, e.g., diseases caused by Pseudomonas aeruginosa, is O provided. The method includes administering to a susceptible human a specified dose of a bispecific antibody that that specifically \" binds Pseudomonas aeruginosa Psl and PcrV. WO 2017/095744 Al MIDEDIMOMMIDIIMMEHMOMINEMOIMINVOIMIE • \"\"\"°\"\"`' — with sequence listing part of description (Rule 5.2(a)) — with international search report (Art. 21(3))
SG11201803794YA 2015-11-30 2016-11-28 Method for preventing or treating nosocomial pneumonia SG11201803794YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260935P 2015-11-30 2015-11-30
PCT/US2016/063865 WO2017095744A1 (en) 2015-11-30 2016-11-28 Method for preventing or treating nosocomial pneumonia

Publications (1)

Publication Number Publication Date
SG11201803794YA true SG11201803794YA (en) 2018-06-28

Family

ID=58798034

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913100WA SG10201913100WA (en) 2015-11-30 2016-11-28 Method for preventing or treating nosocomial pneumonia
SG11201803794YA SG11201803794YA (en) 2015-11-30 2016-11-28 Method for preventing or treating nosocomial pneumonia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913100WA SG10201913100WA (en) 2015-11-30 2016-11-28 Method for preventing or treating nosocomial pneumonia

Country Status (11)

Country Link
US (2) US11066461B2 (en)
EP (1) EP3383884A4 (en)
JP (2) JP7110095B2 (en)
KR (1) KR20180088442A (en)
CN (1) CN108368149A (en)
AU (1) AU2016362202B2 (en)
CA (1) CA3005665A1 (en)
HK (2) HK1254854A1 (en)
IL (1) IL259509A (en)
SG (2) SG10201913100WA (en)
WO (1) WO2017095744A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014100111A (en) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи MOLECULES RELATING TO Psl Pseudomonas, AND WAYS OF THEIR APPLICATION
LT2776065T (en) * 2011-11-07 2020-10-12 Medimmune Limited Combination therapies using anti- pseudomonas psl and pcrv binding molecules
SG10201913100WA (en) 2015-11-30 2020-03-30 Medimmune Ltd Method for preventing or treating nosocomial pneumonia
BR112021023335A2 (en) * 2019-06-11 2022-01-04 Regeneron Pharma Isolated recombinant or antigen-binding fragment thereof and isolated monoclonal or antigen-binding fragment thereof, pharmaceutical composition, isolated polynucleotide molecule, vector, cell, method of decreasing the risk of acquiring p. aeruginosa, and methods of decreasing the bacterial load in a subject with a p. aeruginosa, of increasing survival or the probability of survival of a subject suffering from p. aeruginosa or a subject at risk of infection with p. aeruginosa, to improve or reduce the severity, duration, or frequency of occurrence of at least one symptom of a p. aeruginosa, to increase survival or the likelihood of survival of a subject suffering from cystic fibrosis
IL309559A (en) 2021-07-09 2024-02-01 Luxembourg Inst Of Health Lih Dimeric protein complexes and uses thereof
WO2024003103A1 (en) * 2022-06-29 2024-01-04 Astrazeneca Ab Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0710719T3 (en) 1990-01-12 2007-07-09 Amgen Fremont Inc Generation of xenogenic antibodies
RU2014100111A (en) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи MOLECULES RELATING TO Psl Pseudomonas, AND WAYS OF THEIR APPLICATION
LT2776065T (en) 2011-11-07 2020-10-12 Medimmune Limited Combination therapies using anti- pseudomonas psl and pcrv binding molecules
BR112015010240A2 (en) * 2012-11-06 2017-08-22 Medimmune Ltd COMBINATION THERAPIES THROUGH THE USE OF PSL-BINDING MOLECULES AND ANTI-PSEUDOMONAL PCRV
CA2911209A1 (en) 2013-05-14 2014-11-20 Medimmune, Llc Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof
US20170183397A1 (en) * 2014-05-05 2017-06-29 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (en) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 Treatment of polybacterial infections
SG10201913100WA (en) 2015-11-30 2020-03-30 Medimmune Ltd Method for preventing or treating nosocomial pneumonia

Also Published As

Publication number Publication date
HK1257193A1 (en) 2019-10-18
IL259509A (en) 2018-07-31
JP7110095B2 (en) 2022-08-01
HK1254854A1 (en) 2019-07-26
CA3005665A1 (en) 2017-06-08
WO2017095744A1 (en) 2017-06-08
SG10201913100WA (en) 2020-03-30
EP3383884A1 (en) 2018-10-10
KR20180088442A (en) 2018-08-03
AU2016362202A8 (en) 2018-07-19
EP3383884A4 (en) 2019-07-31
US11066461B2 (en) 2021-07-20
JP2018535227A (en) 2018-11-29
JP2022163050A (en) 2022-10-25
AU2016362202A1 (en) 2018-07-05
US20220041695A1 (en) 2022-02-10
US20180355026A1 (en) 2018-12-13
CN108368149A (en) 2018-08-03
AU2016362202B2 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
SG11201803794YA (en) Method for preventing or treating nosocomial pneumonia
SG11201908391XA (en) Methods for modulating an immune response
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201808125RA (en) Methods for solid tumor treatment
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines